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ABSTRACT
Objectives: Venous thromboembolism (VTE)
continues to be a frequent medical emergency
requiring rapid recognition so as to reach diagnosis
and initiate anticoagulation therapy. The use of statins
in addition to reducing the incidence of arterial
thrombosis for decreasing the incidence and
reoccurrence of VTE is reported. The aim of our study
was to explore the association between statin usage
and the incidence of new VTE at the population level
during a 10-year follow-up.
Design: Population-based historic cohort.
Setting: The Health 2000 Survey was based on a
nationally representative sample.
Participants: 8028 individuals aged 30 years or over
in Finland.
Primary and secondary outcome measures: The
primary end point event was the first ever
hospitalisation due to one of the following causes:
pulmonary embolism (International Classification of
Diseases-10 I26), cerebral venous non-pyogenic
thrombosis (I63.6), or venous thrombosis (I80.9–189).
Results: The preselected explanatory variables applied
to the Poisson regression model were statin usage (no/
yes) during follow-up (2000–2011) and several
baseline data (age, sex; usage of blood glucose
lowering drugs, vitamin K antagonists and antiplatelet
agents). We observed 136 VTE events, the incidence of
1.72 (95% CI 1.44 to 2.04) per 1000 person-years.
Current statin usage did not associate with the
incidence of VTE according to the univariate model
(rate ratio (RR) 0.93, 0.56 to 1.52), but when adjusted
with baseline variables (age, sex, medications) the RR
declined to 0.60 (0.36 to 1.00, p=0.04).
Conclusions: Statin use offers protection against first
ever VTE events and appears as a primary prevention
tool in patients without anticoagulation or antiplatelet
medication.
INTRODUCTION
Venous thromboembolism (VTE) continues
to be a frequent condition demanding
medical emergency attention to reach diag-
nosis and initiate anticoagulation therapy.
Mortality during the few months after VTE
varies between 5% and 20%, and patients
often have other comorbidities, such as car-
diovascular disease and cancer. The yearly
incidence of VTE is 1–2/1000 inhabitants in
western societies. Currently, the traditional
heparin and vitamin K antagonist (VKA)
therapy followed by a course of temporal (3–
6 months) or permanent VKA can be opted
for with novel oral anticoagulants.1
The decision to either continue the antic-
oagulation for a few months or permanently
depends on the acquired or inherited risk
factor proﬁle of the patient. This includes
age above 60 years and concomitant illness,
including cancer and inﬂammatory diseases
as well as obesity, hormonal remedies and
family history or severe thrombophilias (such
as homozygosity of factor V Leiden or pro-
thrombin mutation, double defects, antipho-
spholipid antibody syndrome), subjecting the
patient to recurrent VTE. Despite the clinical
evaluation, the recurrence rate of VTE con-
tinues to be 15–20% after an idiopathic
event and around 5% after a provoked
thrombosis.1 Bleeding tendency needs to be
regularly weighted also against the risk of
thrombosis recurrence, while maintaining
anticoagulation.
The use of statins has been reported to
reduce the incidence of arterial thrombosis;
also, interesting data on the decline of the
incidence and reoccurrence of VTE have
Strengths and limitations of this study
▪ Population based with no selection bias at the
start of follow-up.
▪ Long and complete follow-up information.
▪ Limited number of background variables and
incidence events.
▪ The comprehensive use of prescribed drugs in
this study could not be verified with certainty.
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emerged. Retrospective observational and case–control
studies as well as experimental evidence refer to the pos-
sibility that statins may also exert an antithrombotic
effect in the venous system. A recent meta-analysis
reported the association between VTE and 20–36% pro-
tection with statin use.2 A primary prevention trial of
VTE with rosuvastatin in a randomised placebo-
controlled design showed a 48% reduction in the inci-
dence of VTE.3 Moreover, statin treatment alleviated the
risk of recurrent pulmonary embolism (PE) by 50%
whether the patient used long-term VKA treatment or
had stopped anticoagulation therapy, as reported by a
Dutch population-based study with initially hospitalised
patients.4 Finally, statins decrease the occurrence of VTE
even in patients with cancer.5
Statins reduce the procoagulant activity of platelet
membranes and downplay the signalling via low-density
lipoprotein (LDL) receptors, which are engaged with
the platelet activation.6 Statins also enhance ﬁbrinolysis
by reducing the plasminogen activator inhibitor-1 and
triglyceride concentration. Also, other pleiotropic and
anti-inﬂammatory mechanisms, including dampened
tissue factor expression by monocytes, which can attenu-
ate the risk of thrombosis, have been described.
The aim of the study was to explore the association
between statin usage and incidence of the ﬁrst ever VTE
event in Finland. Our study utilises a nationally repre-
sentative sample of 8028 persons aged >30 years7 of age
in The Health 2000 Survey and a prospective observa-
tional pharmacoepidemiological design.
MATERIAL AND METHODS
Study population
The Health 2000 Survey was based on a nationally repre-
sentative sample of 8028 individuals aged 30 years or
over in Finland. To ensure a sample representative of
the Finnish population, a two-stage stratiﬁed cluster sam-
pling procedure was used. The baseline data collection
from study patients took place between September 2000
and June 2001, and consisted of an interview and a com-
prehensive health examination. Of the study sample,
6986 patients (87%) were interviewed at their home or
in an institution, 6354 patients (79%) took part in a
comprehensive health examination and 416 patients
(5%) were examined at their home.7
Follow-up time and end points
The primary end point event of this study was the ﬁrst
hospitalisation due to one of the following causes: PE
(International Classiﬁcation of Diseases (ICD)-10 I26),
cerebral infarction owing to cerebral venous non-
pyogenic thrombosis (I63.6), or deep vein thrombosis
(DVT), including thrombophlebitis of lower extremities
(I80.0-I80.9). The information on end points was
obtained from the National Hospital Discharge Register,
which covers all hospitalisations in Finland starting from
1969 onwards. The 10-year follow-up was started at the
beginning of The Health 2000 Study and was stopped at
death, end of year 2011 or end point, whichever
occurred ﬁrst. The data regarding deaths were obtained
from Statistics Finland. There were 103 individuals who
recorded primary end point before the start of follow-up
compatible with the general prevalence of the disease;
these patients were excluded from the study population.
Thus, the size of the study population at the start of
follow-up was 7925.
Laboratory measurements
Venous blood samples were drawn from the antecubital
vein after a minimum of 4 h fasting. High-density lipopro-
tein (HDL) cholesterol, total cholesterol, triglyceride and
plasma glucose concentrations were determined enzyma-
tically (Roche Diagnostics, GmbH, Mannheim, Germany
for HDL; and Olympus System Reagent, Hamburg,
Germany for total cholesterol, triglycerides and glucose)
with a clinical chemistry analyser (Olympus, AU400,
Hamburg, Germany).8 C reactive protein (CRP) concen-
trations were determined by a chemiluminescent immu-
nometric assay (Immulite, Diagnostic Products, Los
Angeles, California, USA).8 LDL cholesterol was calcu-
lated using the Friedewald formula. Plasma insulin and
homocysteine concentrations were determined with
microparticle enzyme immunoassay (Abbott
Laboratories, Dainabot, Tokyo, Japan).9 10 S-25(OH)D
concentrations were measured by radioimmunoassay
(Incstar, Stillwater, Minnesota, USA).11
Drug information
The data on the prescribed and purchased drugs were
obtained from registers of the Social Insurance Institution.
We had records of the following drugs classiﬁed by
Anatomical Therapeutic Chemical (ATC) code12: statins
(C10AA), blood glucose lowering drugs excluding insulin
(A10B), insulin (A10A), VKA (B01AA) and antiplatelet
agents excluding heparin (B01AC), and over the counter
acetylsalicylic acid. Regarding statins the data included all
prescribed statins purchased during the follow-up period
in 2000–2006 and 2008. Because there were no data avail-
able regarding the drug amounts purchased for years 2007
and 2009–2011, we calculated the mean amount of pur-
chase based on available years and adapted it for the
whole follow-up period. The time dependent variable for
current statin usage was determined for each individual
with the prescription data using R language package Epi.13
The follow-up time of each individual with statin exposure
was cut into 6-month periods and the statin usage in each
period was determined. For other drugs we had only the
number of prescriptions at the baseline year 2000, which
was used to construct a dichotomic variable of drug usage
at baseline (no/yes).
Statistical modelling
We applied the Poisson regression model using end
point event as a dependent variable, length of follow-up
as an offset variable and statin usage (no/yes) during
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each time period as time-varying explanatory variable.
The following variables were used as time-invariant vari-
ables measured at baseline: age (30–40, 40–50, 50–60,
60–70 and over 70 years), sex (male/female), blood
glucose lowering drug usage, excluding insulins (no/
yes), insulin usage (no/yes), VKA usage (no/yes), anti-
platelet agents (no/yes), blood glucose (mmol/L), total
cholesterol (mmol/L), HDL cholesterol (mmol/L),
LDL cholesterol (mmol/L), triglycerides (mmol/L),
CRP (mg/L), vitamin D3 (nmol/L), homocysteine
(µmol/L) and insulin (mU/L). The values of the
laboratory measurements were transformed to categor-
ical variables deﬁned by tertiles. We also estimated the
inverse probability weights (IPW) to ﬁt marginal struc-
tural models.14 IPW were estimated using age and sex in
the numerator, and age, sex, usage of blood glucose low-
ering drugs other than insulin, VKA usage and use of
antiplatelet agents in the denominator. In order to
check survivor bias we carried out modelling without
patients with prevalent statin use in start of follow-up
(N=460 excluded).15
RESULTS
The size of the study population was 7925, including
3589 men and 4336 women (table 1). We observed 136
VTE events during follow-up with incidence of 1.72
(95% CI 1.44 to 2.04) per 1000 person-years during the
mean follow-up time of 10 years (table 2). There were
64 events with diagnosis of PE (ICD-10 I26), 1 with sinus
thrombosis (I636) and 71 with DVT (I80.0–I80.9).
In all there were 67 532 statin prescriptions and 2083 indi-
viduals (26% of the study population) had at least 1 pre-
scription. Simvastatin (ATC code C10AA01) with 54% of
prescriptions and atorvastatin (C10AA05) with 23% repre-
sented the most frequent active lipid-lowering substances.
Current statin usage, which comprised 14% of all cumu-
lated person-years, did not associate with the incidence of
VTE according to the univariate model rate ratio (RR) 0.93
(0.56 to 1.52; table 2). The use of oral antidiabetic drugs at
the baseline was associated with a threefold increased inci-
dence (RR 3.32, 1.84 to 6.00), but insulin usage did not
show any association. Using antithrombotic drugs associated
with higher incidence (RR 4.55, 2.70 to 7.66).
Table 1 Baseline characteristics of study population
Categorical variables and usage of drugs at baseline
Sex
Male 3589 45%
Female 4336 55%
Blood glucose lowering drug
No 7637 96%
Yes 288 4%
Insulin
No 7787 98%
Yes 138 2%
Antithrombotic agent
No 7582 96%
Yes 343 4%
Antiplatelet agent
No 7764 98%
Yes 161 2%
Vitamin K antagonists
No 7732 98%
Yes 193 2%
Continuous variables at baseline LDL cholesterol (mmol/L)
1st Qu Median Mean 3rd Qu SD Missing
Age 42.0 52.0 54.7 66.0 16.1 0
Blood glucose (mmol/L) 5.0 5.3 5.6 5.7 1.3 1275
Total cholesterol (mmol/L) 5.1 5.9 5.9 6.6 1.1 1275
HDL cholesterol (mmol/L) 1.1 1.3 1.3 1.6 0.4 1275
LDL cholesterol (mmol/L) 3.1 3.8 3.8 4.5 1.2 1276
Triglycerides (mmol/L) 1.0 1.3 1.6 1.9 1.1 1275
Ratio HDL/cholesterol 18.0 22.0 23.0 28.0 7.4 1275
CRP (mg/L) 0.3 0.8 2.3 2.0 6.3 1694
Vitamin D3 (nmol/L) 33.0 43.0 44.9 55.0 16.9 1825
Homocysteine (µmol/L) 9.2 11.0 12.0 13.5 5.1 1825
Insulin (mU/L) 5.0 7.0 9.6 11.0 30.3 1627
CRP, C reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Qu, quartile.
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Table 2 Incidence of end point events
Variable P-years (1000) Events Incidence (1/1000) 95% CI RR 95% CI
Current statin usage
No 67.78 118 1.74 1.44 2.09
Yes 11.17 18 1.61 0.95 2.55 0.93 0.56 1.52
Sex
Male 36.02 53 1.47 1.1 1.93
Female 42.93 83 1.93 1.54 2.4 1.31 0.93 1.85
Age
(0, 40] 19.92 10 0.50 0.24 0.92
(40, 50] 20.22 15 0.74 0.41 1.22 1.48 0.66 3.29
(50, 60] 17.11 24 1.40 0.90 2.09 2.79 1.34 5.84
(60, 70] 11.05 28 2.53 1.68 3.66 5.05 2.45 10.39
(70, Inf] 10.65 59 5.54 4.22 7.15 11.04 5.65 21.58
Insulin usage at baseline
No 77.83 133 1.71 1.43 2.03
Yes 1.12 3 2.68 0.55 7.83 1.57 0.50 4.92
Blood glucose lowering drug
No 76.71 124 1.62 1.34 1.93
Yes 2.24 12 5.37 2.77 9.37 3.32 1.84 6.00
Antithrombotic agent usage
No 76.7 120 1.56 1.30 1.87
Yes 2.25 16 7.11 4.06 11.55 4.55 2.70 7.66
Antiplatelet agents usage
No 77.87 126 1.62 1.35 1.93
Yes 1.08 10 9.27 4.44 17.05 5.73 3.01 10.91
Vitamin K antagonists usage
No 77.7 128 1.65 1.37 1.96
Yes 1.25 8 6.42 2.77 12.66 3.90 1.91 7.97
Blood glucose (mmol/L)
[2.4, 5.1] 24.79 36 1.45 1.02 2.01
(5.1, 5.6] 23.93 31 1.30 0.88 1.84 0.89 0.55 1.44
(5.6, 26.7] 18.69 48 2.57 1.89 3.40 1.77 1.15 2.72
Total cholesterol (mmol/L)
[1.9, 5.4] 23.71 36 1.52 1.06 2.10
(5.4, 6.3] 21.33 33 1.55 1.06 1.02 0.64 1.63 1.02
(6.3, 11.7] 22.38 46 2.06 1.50 1.35 0.88 2.09 1.35
HDL cholesterol (mmol/L)
[0.23, 1.13] 22.39 45 2.01 1.46
(1.13, 1.45] 22.45 33 1.47 1.01 0.73 0.47 1.15 0.73
(1.45, 3.41] 22.57 37 1.64 1.15 0.82 0.53 1.26 0.82
LDL cholesterol (mmol/L)
[0, 3.3] 22.56 34 1.51 1.04
(3.3, 4.2] 22.79 38 1.67 1.18 1.11 0.70 1.76 1.11
(4.2, 8.8] 22.06 43 1.95 1.41 1.29 0.82 2.03 1.29
Triglycerides (mmol/L)
[0.4, 1.1] 26.16 30 1.15 0.77
(1.1, 1.7] 21.84 45 2.06 1.50 1.80 1.13 2.85 1.80
(1.7, 16.6] 19.42 40 2.06 1.47 1.80 1.12 2.88 1.80
Ratio HDL/cholesterol
[3, 19] 23.92 48 2.01 1.48
(19, 25.7] 20.58 34 1.65 1.14 0.82 0.53 1.28 0.82
(25.7, 56] 22.91 33 1.44 0.99 0.72 0.46 1.12 0.72
C reactive protein (mg/L)
[0, 0.39] 22.26 22 0.99 0.62
(0.39, 1.41] 21.62 42 1.94 1.40 1.97 1.17 3.29 1.97
(1.41, 191] 20.53 40 1.95 1.39 1.97 1.17 3.32 1.97
Vitamin D3 (nmol/L)
[5, 36] 20.55 35 1.70 1.19 2.37
(36, 50] 21.42 31 1.45 0.98 2.06 0.85 0.52 1.38
(50, 134] 21.15 37 1.75 1.23 2.41 1.03 0.65 1.63
Continued
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Addition of more explanatory variables in the model
substantially altered the association between statin usage
and incidence (table 3). Adjusting for sex, age, baseline
oral antidiabetic, insulin and use of antithrombotics
(model II) reduced the RR to 0.60 (0.36 to 1.00). Using
IPW for the structural model (model III) decreased the
RR further to 0.58 (0.35 to 0.96). Adjusting for baseline
laboratory measurements also decreased slightly the esti-
mate for statin effect, for example, adjusting for CRP
gave a RR of 0.43 (0.23 to 0.81). However, because of the
missing laboratory measurements we do not report these
results in further detail, for example, for CRP there were
several (1694) missing values (table 2). Increased levels
of LDL were associated with increasing incidence of VTE;
the same occurred with homocysteine.
In addition, we looked for possible interactions
between statin usage and age, sex, blood glucose lower-
ing drugs usage (excluding use of insulin), VKA and
Table 2 Continued
Variable P-years (1000) Events Incidence (1/1000) 95% CI RR 95% CI
Homocysteine (µmol/L)
[3.7, 9.7] 22.15 18 0.81 0.48 1.29
(9.7, 12.5] 21.82 32 1.47 1.00 2.07 1.80 1.01 3.22
(12.5, 111] 19.16 53 2.77 2.07 3.62 3.40 1.99 5.81
Insulin (mU/L)
[1, 5] 22.72 26 1.14 0.75 1.68
(5, 9] 22.67 45 1.99 1.45 2.66 1.73 1.07 2.81
(92 200] 19.64 33 1.68 1.16 2.36 1.47 0.88 2.00
RR with 95% CI based on univariate Poisson regression model.
Laboratory measurements in tertiles ‘[a,b)’ means that interval a–b is closed left and open right. The data on variables are collected at
baseline.
HDL, high-density lipoprotein; LDL, low-density lipoprotein; RR, rate ratio.
Table 3 RR with 95% CI of three Poisson regression models
Model I Model II Model III
RR (95% CI) RR (95% CI) RR, IPW (95% CI)
Statin
No (reference) (reference) (reference)
Current 0.64 0.38 1.05 0.60 0.36 1.00 0.58 0.35 0.96
Age
Under 40 (reference) (reference) (reference)
(40, 50] 1.52 0.68 3.38 1.51 0.68 3.37 1.53 0.68 3.43
(50, 60] 2.99 1.42 6.26 2.91 1.39 6.10 3.20 1.53 6.70
(60, 70] 5.66 2.73 11.75 5.31 2.55 11.05 5.36 2.55 11.24
(70, Inf] 11.68 5.94 22.95 9.92 4.99 19.74 9.93 4.95 19.92
Sex
Male (reference) (reference) (reference)
Female 1.02 0.72 1.45 1.02 0.72 1.46 0.99 0.70 1.41
Blood glucose lowering drug
No (reference) (reference)
Yes 1.89 0.98 3.63 1.63 0.86 3.11
Insulin usage
No (reference) (reference)
Yes 0.72 0.21 2.45 0.72 0.25 2.13
Vitamin K antagonists
No (reference) (reference)
Yes 1.46 0.69 3.07 1.38 0.68 2.80
Antiplatelet agents
No (reference) (reference)
Yes 2.33 1.20 4.53 2.60 1.42 4.76
Model I included only statin, age and sex as covariates. Models II and III included blood glucose lowering drug, insulin usage, vitamin K
antagonists usage and antiplatelet agents usage as covariates. IPW Model III is based on stabilised weights for statin usage. In IPW model
age and sex were in numerator; and age, sex, baseline oral antidiabetics, baseline insulin and baseline anticoagulant usage were in
denominator.
IPW, inverse probability weights; RR, rate ratio.
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platelet aggregation inhibitors. Interaction for sex and
statin usage was signiﬁcant (χ2=6.310, df=1, p=0.012).
Interestingly, it turned out that the incidence of VTE
among the statin group for men was quite low (RR 0.22,
0.06 to 0.65), but for women such an association was not
obvious (RR 0.75, 0.41 to 1.38), on comparing VTE with
and without statin usage, respectively (table 4).
In sensitivity analyses without prevalent statin users
there were 115 cases in the non-statin group and 10
cases in the statin group; unadjusted RR was 0.82 (0.43
to 1.56) and adjusted was 0.63 (0.33 to 1.21).
DISCUSSION
To the best of our knowledge, this is the ﬁrst report
studying the association between statin usage and VTE
that utilises a nationally representative population
sample. Our results during the 11 years of prospective
follow-up on the incidence of VTE are in line with a
recent meta-analysis,16 which showed the risk reduction
of 0.89 (0.78 to 1.01) for VTE among statin users. The
JUPITER study, which is the largest randomised trial,
included 465 events and showed 36% reduction in VTE
(RR 0.64, 0.39 to 1.06, p=0.08).3 17 Our study addressed
new incidence of VTE, as those patients who had previ-
ously suffered from VTE (136/8028) were excluded
from the study population. The prospective nature and
large population-based design of pharmacoepidemiology
are the strengths of our study.
In this freely living Finnish population sample we
could demonstrate that statin use is associated with a
reduction of the incidence of VTE, including DVT of
the lower extremities, PE and one case of cerebrovascu-
lar sinus thrombosis. This adds to the conﬁrmation that
statins exert anticoagulant activity.2–5 Furthermore, it
supports the idea that statin therapy could be implemen-
ted in patients at risk of VTE.
We observed that use of oral antidiabetic drugs at base-
line was associated with a threefold-increased incidence
(RR 3.32, 1.84 to 6.00) of VTE, which indicates that
insulin-resistant patients carry a high risk of VTE and that
oral antidiabetic drugs do not seem to alleviate this risk,
while insulin may do so.18 The positive association
between antithrombotic drugs and VTE is quite probably
due to confounding by indication19; also, the
co-occurrence of cardiovascular disease and VTE has been
noted in several studies.20 The limitation of our study is
based on the fact that over-the-counter aspirin use is not
controlled. This is signiﬁcant, as aspirin has been recently
shown to inhibit the reoccurrence of idiopathic VTE.21
Men seemed to respond to statin use more favourably
than did women, indicating a plausible hormonal regu-
lation of the effect of statins. In women, we did not
control for hormonal replacement therapy, which may
be a confounding factor, and which is known to be a
risk factor for VTE.22 23 The well-known age-association
in increasing the incidence of DVT and PE was evi-
denced also among our patients. Also, the overall inci-
dence of VTE in Finland is compatible with what has
been reported internationally. The protective association
with incidence of VTE among the highest third tertile of
HDL–LDL ratio, lowest homocysteine and CRP supports
earlier results of these surrogate laboratory markers.
Several limitations must be kept in mind when evaluat-
ing results from any observational study based on record
linkage of drug information. First, the comprehensive
use of prescribed drugs in this study could not be veri-
ﬁed with certainty and may be subject to misclassiﬁca-
tion. The prescription data do not contain information
on drugs used in nursing homes; therefore, the mis-
classiﬁcation of exposure is more likely among the older
patient groups. Second, although model-based adjust-
ments using regression and IPW were applied, it is
always possible that residual confounding factors could
inﬂuence the results. For example, statin usage may
depend on variables that are not included in the statis-
tical models; or the statistical models used in the analysis
do not properly adjust for the confounding factors. The
importance of adjusting for possible confounding effects
is reﬂected by the large difference between estimates
obtained from the univariate and multivariate models.
On the other hand, the results based on the three
models with different patterns of covariates and model-
ling technique remained nearly unchanged regarding
the effect of current statin usage (table 3). This compati-
bility increases the credibility of the results, albeit the
actual incidences are relatively low in numbers due to
the natural incidence of 1–2 cases/1000 inhabitants
annually. Also, the hospital records, which are nationally
gathered, may suffer from inconsistencies. Recently,
these were evaluated in a separate study which validated
this form of data collection in PE, but not in DVT.24
Third, analyses without prevalent statin showed attenu-
ated, not signiﬁcant, effect, which may be due to lower
effect and lower number of cases resulting in wider con-
ﬁdence limits.
Table 4 Statin usage and sex, interaction model
P-years Events Incidence (95% CI) RR (95% CI)
No statin/male 30.57 50 1.64 1.21 2.16 (reference)
Statin/male 5.45 3 0.55 0.11 1.61 0.20 0.06 0.65
No Statin/female 37.21 68 1.83 1.42 2.32 0.87 0.60 1.27
Statin/female 5.72 15 2.62 1.47 4.33 0.75 0.41 1.38
Model included age, blood glucose lowering drug, insulin usage, vitamin K antagonists usage and antiplatelet agents usage as covariates.
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In conclusion, statin use offers protection against ﬁrst-
ever VTE events. The elevated LDL cholesterol, CRP
and homocysteine, as reported earlier, are also asso-
ciated with the risk of new VTE. Statins appear as a
primary prevention tool in patients with a high risk of
VTE, exerting its best effect in the male population.
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